Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial

Diabetes, Obesity and Metabolism

Volumn 11, Issue 6, 2009, Pages 611-622

  Jadzinsky, M ^a,e   Pfutzner A ^b,e   Paz Pacheco, E ^c,e   Xu, Z ^d   Allen, E ^d   Chen, Roland ^d   Antunez, P ^e   Baccaro, C ^e   Bertone, R ^e   Bragagnolo, J ^e   Cordo, C S ^e   Dieuzeide, G ^e   Fideleff, H L ^e   Hermida, S ^e   Herrera, J ^e   Issa, C ^e   Kraft, M ^e   Maffei, L ^e   Man, Z ^e   Marcucci, G ^e   Oviedo, A ^e   Sanchez, J M ^e   Vines, G ^e   Zambon, F ^e   Chacra, A ^e   Farias, F ^e   Felicio, J ^e   Forti, A ^e   Gross, J L ^e   Hissa, M N ^e   Rassi, N ^e   Sgarbi, J A ^e   Barakat, A ^e   Bohm G F ^e   Hanefeld, M ^e   Illies, G ^e   Kellner, A ^e   Klausmann, G ^e   Klein, C ^e   Molle, A ^e   Nauck, M ^e   Sauter, J ^e   Schaller, J ^e   Wachter, J ^e   Deak G ^e   Dudas M ^e   Foldesi, I ^e   Harcsa, E ^e   Salamon, C ^e   Agarwal, R P ^e   Aravind, S R ^e   Dharmalingam, M ^e   Jugal Bihari, G ^e   Kale, S ^e   Kalra, S ^e   Kumar, P ^e   Mahadevan, S ^e   Mohan, V ^e   Rao, P ^e   Shah, S ^e,e   Thomas, N ^e   Wangnoo, S K ^e   Bosi, E ^e   Cocchi, R ^e   Cordera, R ^e   Perriello, G ^e   Squatrito, S ^e   Arechavaleta Granell, M D R ^e   Galvez Correa, G ^e   Garcia Hernandez, P A ^e   Hernandez, N ^e   Jerjes Sanchez, C ^e   Jimenez Ramos, S A ^e   Lozano, F ^e   Reyes, C ^e   Robles Torres, F J ^e   Sauque Reyna, L ^e   Tamez Perez, H E ^e   Velazquez, M V ^e   Villegas, E M ^e   Cimafranca, K ^e   Denopol, M ^e   Jimeno, C ^e   Lim Abrahan, M ^e   Liwag, A ^e   Panelo, A A ^e   Tan, G H ^e   Derezinski, T ^e   Galczak, W ^e   Jasieniak Pinis, G ^e   Mrozek, J ^e   Petryka, R ^e   Skokowska, E ^e   Stasinska, T ^e   Strojek, K ^e   Abreu Feshold, F ^e   Barranco, E ^e   Claudio, J ^e   Sosa Padilla, M ^e   Vazquez Tanus, J ^e   Velazquez Navarro, S ^e   Antciferov, M ^e   Arutunov, G ^e   Balabolkin, M ^e   Barbarash, O ^e   Bokarev, I ^e   Bondar, I ^e   Bova, E ^e   Dreval, A ^e   Grineva, E ^e   Gurieva, I ^e   Ivanova, L ^e   Ivleva, A ^e   Khalimov, Y ^e   Kobalava, Z ^e   Kotelnikov, M ^e   Lantseva, O ^e   Marasaev, V ^e   Nedogoda, S ^e   Nosova, N ^e   Ponomareva, A ^e   Radygina, E ^e   Ragozin, A ^e   Rakov, A ^e   Rebrov, A ^e   Reshedko, G ^e   Reshetko, O ^e   Rodionova, T ^e   Rodoman, G ^e   Ruyatkina, L ^e   Semenova, O ^e   Sherenkov, A ^e   Shustov, S ^e   Shvarts, Y ^e   Smirnova, E ^e   Solovyev, O ^e   Strongin, L ^e   Suplotova, L ^e   Trusov, V ^e   Vorobyev, S ^e   Vorokhobina, N ^e   Voychik, E ^e   Yakusevich, V ^e   Zagrebelnaya, O ^e   Zalevskaya, A ^e   Zanozina, O ^e   Zhavoronkova, N ^e   Zhukova, L ^e   Bazylevych, A ^e   Girina, O ^e   Levchenko, O ^e   Netiazhenko, V ^e   Perepelytsya, M ^e   Pertseva, T ^e   Rudyk, Y ^e   Slyvka, Y ^e   Vlasenko, M ^e   Yagensky, A ^e   Ashley, R ^e   Atiee, G ^e   Bleser, S D ^e   Bright, D K ^e   Bueso, G ^e   Buth, D K ^e   Cabasares, H ^e   Campolo, M E ^e   Chappel, C ^e   Conard, S E ^e   Constantine, J ^e   Dayon, D L ^e   Dionne, D ^e   Fenton, I F ^e   Garcia, R ^e   George, A ^e   Gilman, R ^e   Glaser, L ^e   Gollapudi, M ^e   Gray, J ^e   Henry III, W J ^e   Iranmanesh, A ^e   Ison, R ^e   Jacks, R K ^e   Jacks, W ^e   Jain, M ^e   Johnson Jr , G ^e   Kaplan, R ^e   Khairi, R A ^e   LaBuda, J ^e   LaSalle, J ^e   Lawrence, M K ^e   Lipetz, R S ^e   Miller, S ^e   Montoro, R ^e   Mora, Y ^e   Poindexter III, A ^e   Quigley, J F ^e   Raad, G L ^e   Rawtani, P ^e   Schneider, A ^e   Spence, J ^e   Stanton, D ^e   Sugimoto, D ^e   Thomas, F L ^e   Weiss, D ^e   Weissman, P ^e   Woodward, W R ^e   more..

^a HOSPITAL DURAND   (Argentina)

^b Institute for Clinical Research and Development   (Germany)

^c Department of Internal Medicine   (Philippines)

^d BRISTOL MYERS SQUIBB   (United States)

^e NONE

Author keywords

DPP 4; Metformin; Saxagliptin; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DISEASE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; LYMPHOCYTE COUNT; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYSTOLIC BLOOD PRESSURE;

EID: 65549123794     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01056.x     Document Type: Article

References (27)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
2. Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin-based therapies for type 2 diabetes: Incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev 2008; 4: 101-109.
3. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10 year follow-up of intensive glucose control in type 2 diabetes. UKPDS 80. N Engl J Med 2008; 359: 1577-1589.
5. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335-1343.
6. Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 741-750.
7. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987.
8. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 175-185.
9. Deacon CF, Carr RD, Holst JJ. DPP-4 inhibitor therapy: New directions in the treatment of type 2 diabetes. Front Biosci 2008; 13: 1780-1794.
10. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007; 23: 945-952.
11. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721.
12. Mannucci E, Ognibene A, Cremasco F et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24: 489-494.
13. Migoya EM, Miller J, Larson P et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Abstract 0286-OR. Diabetes Abstract Book, American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22-26 June 2007.
14. Rodbard HW, Blonde L, Braithwaite SS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13: 1-68.
15. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S1-S215.
16. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
17. Augeri DJ, Robl JA, Betebenner DA et al. Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 5025-5037.
18. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 376-386.
19. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
20. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24: 539-548.
21. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-1478.
22. Laska EM, Meisner MJ. Testing whether an identified treatment is best. Biometrics 1989; 45: 1139-1151.
23. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
24. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2007; 30: S4-S41.
25. Marchetti P, Dotta F, Lauro D, Purrello F. An overview of pancreatic beta-cells defects in human type 2 diabetes: Implications for treatment. Regul Pept 2008; 146: 4-11.
26. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
27. Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006; 8: 650-660.